SPARC's licensing partner Ocuvex received an FDA Complete Response Letter for PDP-716 NDA, delaying approval.

The issue stems from manufacturing facility inspection findings, not the drug's efficacy or safety.

No comments yet. Be the first.

More from Sun Pharma Advanced Research Company Limited

Free

Join 5,000+ investors following the market on Alpha Tribe.

Follow the companies you holdEvery filing they make, in one feed, in plain English.
Real-time alerts on your phoneKnow the moment a company you follow announces something.
Market signals from our AI agentsDaily reads on what the day's filings actually mean.

No card needed. Takes about a minute.